196 related articles for article (PubMed ID: 34791809)
1. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery.
Cameron ME; Underwood PW; Williams IE; George TJ; Judge SM; Yarrow JF; Trevino JG; Judge AR
Cancer Med; 2022 Jan; 11(1):50-60. PubMed ID: 34791809
[TBL] [Abstract][Full Text] [Related]
2. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.
Sah RP; Sharma A; Nagpal S; Patlolla SH; Sharma A; Kandlakunta H; Anani V; Angom RS; Kamboj AK; Ahmed N; Mohapatra S; Vivekanandhan S; Philbrick KA; Weston A; Takahashi N; Kirkland J; Javeed N; Matveyenko A; Levy MJ; Mukhopadhyay D; Chari ST
Gastroenterology; 2019 May; 156(6):1742-1752. PubMed ID: 30677401
[TBL] [Abstract][Full Text] [Related]
3. The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective study based on a large population.
Shen XD; Wang X; Zheng ZJ; Chen YH; Tan CL; Liu XB; Ke NW
Cancer Med; 2023 May; 12(9):10438-10448. PubMed ID: 36938648
[TBL] [Abstract][Full Text] [Related]
4. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
[TBL] [Abstract][Full Text] [Related]
5. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma.
Yanagaki M; Onda S; Gocho T; Igarashi Y; Shirai Y; Okui N; Matsumoto M; Sakamoto T; Haruki K; Ikegami T
Langenbecks Arch Surg; 2024 Apr; 409(1):130. PubMed ID: 38634913
[TBL] [Abstract][Full Text] [Related]
7. Cachexia worsens prognosis in patients with resectable pancreatic cancer.
Bachmann J; Heiligensetzer M; Krakowski-Roosen H; Büchler MW; Friess H; Martignoni ME
J Gastrointest Surg; 2008 Jul; 12(7):1193-201. PubMed ID: 18347879
[TBL] [Abstract][Full Text] [Related]
8. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma.
Mitsunaga S; Kasamatsu E; Machii K
Support Care Cancer; 2020 Nov; 28(11):5271-5279. PubMed ID: 32103356
[TBL] [Abstract][Full Text] [Related]
9. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.
Ozola Zalite I; Zykus R; Francisco Gonzalez M; Saygili F; Pukitis A; Gaujoux S; Charnley RM; Lyadov V
Pancreatology; 2015; 15(1):19-24. PubMed ID: 25524484
[TBL] [Abstract][Full Text] [Related]
10. Brain metabolites in cholinergic and glutamatergic pathways are altered by pancreatic cancer cachexia.
Winnard PT; Bharti SK; Sharma RK; Krishnamachary B; Mironchik Y; Penet MF; Goggins MG; Maitra A; Kamel I; Horton KM; Jacobs MA; Bhujwalla ZM
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1487-1500. PubMed ID: 33006443
[TBL] [Abstract][Full Text] [Related]
11. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.
Masuda S; Yamakawa K; Masuda A; Toyama H; Sofue K; Nanno Y; Komatsu S; Omiya S; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Ashina S; Gonda M; Abe S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Kanzawa M; Itoh T; Fukumoto T; Kodama Y
Ann Surg Oncol; 2023 Sep; 30(9):5776-5787. PubMed ID: 37191859
[TBL] [Abstract][Full Text] [Related]
12. CT-based screening of sarcopenia and its role in cachexia syndrome in pancreatic cancer.
Khristenko E; Sinitsyn V; Rieden T; Girod P; Kauczor HU; Mayer P; Klauss M; Lyadov V
PLoS One; 2024; 19(1):e0291185. PubMed ID: 38271373
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia.
Gresham G; Placencio-Hickok VR; Lauzon M; Nguyen T; Kim H; Mehta S; Paski S; Pandol SJ; Osipov A; Gong J; Jamil LH; Nissen N; Lo SK; Hendifar AE
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1959-1968. PubMed ID: 34609081
[TBL] [Abstract][Full Text] [Related]
14. Role of noncoding RNAs in pancreatic ductal adenocarcinoma associated cachexia.
Uddin MH; Mohammad RM; Philip PA; Azmi AS; Muqbil I
Am J Physiol Cell Physiol; 2022 Dec; 323(6):C1624-C1632. PubMed ID: 36280389
[TBL] [Abstract][Full Text] [Related]
15. Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.
Prokopchuk O; Grünwald B; Nitsche U; Jäger C; Prokopchuk OL; Schubert EC; Friess H; Martignoni ME; Krüger A
BMC Cancer; 2018 Feb; 18(1):128. PubMed ID: 29394913
[TBL] [Abstract][Full Text] [Related]
16. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of Preoperative Osteosarcopenia for Patients with Pancreatic Ductal Adenocarcinoma After Curative Resection.
Abe T; Nakata K; Nakamura S; Ideno N; Ikenaga N; Fujita N; Ishigami K; Nishihara K; Nakamura M
Ann Surg Oncol; 2023 Oct; 30(11):6673-6679. PubMed ID: 37466870
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
19. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients.
Avan A; Avan A; Le Large TY; Mambrini A; Funel N; Maftouh M; Ghayour-Mobarhan M; Cantore M; Boggi U; Peters GJ; Pacetti P; Giovannetti E
PLoS One; 2014; 9(9):e108057. PubMed ID: 25238546
[TBL] [Abstract][Full Text] [Related]
20. Impact of osteopenia on surgical and oncological outcomes in patients with pancreatic cancer.
Abe K; Furukawa K; Okamoto T; Matsumoto M; Futagawa Y; Haruki K; Shirai Y; Ikegami T
Int J Clin Oncol; 2021 Oct; 26(10):1929-1937. PubMed ID: 34232427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
